The first MedChemComm “Accepted Manuscript” is now published. Jacqueline Marchand-Brynaert (Université catholique de Louvain, Belgium) and colleagues’ article is now available to download.
All MedChemComm authors now have the opportunity to have the unedited version of their article published shortly after acceptance, meaning that results are now published, in citable form, even earlier than before. More details…..
This month sees the following articles in MedChemComm that are in the top ten most accessed:
Molecular obesity, potency and other addictions in drug discovery
Michael M. Hann
Med. Chem. Commun., 2011, 2, 349-355
DOI: 10.1039/C1MD00017A
Synthesis and biological evaluation of 2,3-bis(het)aryl-4-azaindole derivatives as protein kinase inhibitors
Frédéric Pin, Frédéric Buron, Fabienne Saab, Lionel Colliandre, Stéphane Bourg, Françoise Schoentgen, Remy Le Guevel, Christiane Guillouzo and Sylvain Routier
Med. Chem. Commun., 2011, 2, 899-903
DOI: 10.1039/C1MD00141H
Design, synthesis, and structure–activity relationships of 1,3,4-oxadiazol-2(3H)-ones as novel FAAH inhibitors
László E. Kiss, Humberto S. Ferreira, Alexandre Beliaev, Leonel Torrão, Maria João Bonifácio and David A. Learmonth
Med. Chem. Commun., 2011, 2, 889-894
DOI: 10.1039/C1MD00136A
Minisci reactions: Versatile CH-functionalizations for medicinal chemists
Matthew A. J. Duncton
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00134E
Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space
Alexander Alex, David S. Millan, Manuel Perez, Florian Wakenhut and Gavin A. Whitlock
Med. Chem. Commun., 2011, 2, 669-674
DOI: 10.1039/C1MD00093D
Are pyridazines privileged structures?
Camille G. Wermuth
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00074H
Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes
Jeffrey A. Pfefferkorn, Angel Guzman-Perez, Peter J. Oates, John Litchfield, Gary Aspnes, Arindrajit Basak, John Benbow, Martin A. Berliner, Jianwei Bian, Chulho Choi, Kevin Freeman-Cook, Jeffrey W. Corbett, Mary Didiuk, Joshua R. Dunetz, Kevin J. Filipski, William M. Hungerford, Christopher S. Jones, Kapil Karki, Anthony Ling, Jian-Cheng Li, Leena Patel, Christian Perreault, Hud Risley, James Saenz, Wei Song, Meihua Tu, Robert Aiello, Karen Atkinson, Nicole Barucci, David Beebe, Patricia Bourassa, Francis Bourbounais, Anne M. Brodeur, Rena Burbey, Jing Chen, Theresa D’Aquila, David R. Derksen, Nahor Haddish-Berhane, Cong Huang, James Landro, Amanda Lee Lapworth, Margit MacDougall, David Perregaux, John Pettersen, Alan Robertson, Beijing Tan, Judith L. Treadway, Shenping Liu, Xiayang Qiu, John Knafels, Mark Ammirati, Xi Song, Paul DaSilva-Jardine, Spiros Liras, Laurel Sweet and Timothy P. Rolph
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/c1md00116g
Development of substituted 7-phenyl-4-aminobenzothieno[3,2-d] pyrimidines as potent LIMK1 inhibitors
Brad E. Sleebs, Danny Ganame, Alla Levit, Ian P. Street, Alison Gregg, Hendrik Falk and Jonathan B. Baell
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00138H
Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt’s lymphoma cytotoxicity
Michael N. Gandy, Matthew McIldowie, Katie Lewis, Agata M. Wasik, Danielle Salomonczyk, Keith Wagg, Zak A. Millar, David Tindiglia, Philippe Huot, Tom Johnston, Sherri Thiele, Blake Nguyen, Nicholas M. Barnes, Jonathan M. Brotchie, Mathew T. Martin-Iverson, Joanne Nash, John Gordon and Matthew J. Piggott
Med. Chem. Commun., 2010, 1, 287-293
DOI: 10.1039/C0MD00108B
Identification of 3-aminothieno[2,3-b]pyridine-2-carboxamides and 4-aminobenzothieno[3,2-d]pyrimidines as LIMK1 inhibitors
Brad E. Sleebs, Alla Levit, Ian P. Street, Hendrik Falk, Tim Hammonds, Ai Ching Wong, Mark D. Charles, Michael F. Olson and Jonathan B. Baell
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00137J
Why not take a look at the articles today and blog your thoughts and comments below.
Fancy submitting an article to MedChemComm? Then why not submit to us today or alternatively email us your suggestions.
Biocompatible nanovalves can effectively store and protect drugs inside nano-reservoirs, then deliver and release them to kill targeted cancer cells under external stimuli. As such they are a promising example of smart materials that are devised to both address the controlled release of the therapeutics and selectively target diseased cells.
In this recent MedChemComm review article, Ying Wei Yang from Jilin University, Changchun (P.R China) provides a timely and comprehensive update on the recent progress of biocompatible nanovales based on mesoporous silica nanoparticles. The review highlights the cutting-edge progress in this field, with details of the nanovalves construction, therapeutic release mechanisms, while specifically focusing on the water-based systems for therapeutic applications.
Whether you are in the Medical, Materials or Chemistry field, this MedChemComm review is for you!
Free to access for the next 4 weeks.
Towards biocompatible nanovalves based on mesoporous silica nanoparticles Ying-Wei Yang
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00158B, Review
In this MedChemComm review Matthew Duncton, Renovis Inc., highlights the attractive potential of Minisci reactions – addition of radicals to heteroaromatic bases – for medicinal and biological chemists.
These reactions can be used to introduce a broad-range of selective CH-functionalization groups, such as alkyls, cycloalkyls, sugars, esters and more. In many cases, these processes are highly chemo- and regio-selective, making them ideal for industrial applications, because complicating factors such as protecting group strategies can be avoided.
Read this review now for specific examples and future developments of these useful reactions. It’s free to download for the next 4 weeks!
Minisci reactions: Versatile CH-functionalizations for medicinal chemists
Matthew A. J. Duncton, Med. Chem. Commun., 2011, DOI: 10.1039/C1MD00134E
This week, the RSC launched a new product, RSC e-membership, allowing anyone to access an electronic version of Chemistry World through a MyRSC account and to enjoy the benefits of electronic networking via this professional online community for £20/year.
Subscribers to this do not benefit from the professional recognition or any of the other many services and discounts available to RSC Members, but it allows chemists from around the world, many already members of another chemical society in their own country, to benefit from the highly-esteemed content in Chemistry World and the networking opportunities offered from MyRSC, which now stands at over 11,000 members. The RSC e-membership also allows subscribers to join a virtual specialist interest group on MyRSC. If you are interested in joining, please visit www.rsc.org/emembership.
Welcome to MedChemComm Issue 9.
Ahmed Kamal and colleagues from the Indian Institute of Chemical Technology in Hyderabad (India) have devised a series of novel 2-Anilinonicotinyl linked 1,3,4-oxadiazole derivatives through simple synthetic schemes that exhibit potent anticancer efficacy via the inhibition of tubulin polymerisation, thus blocking mitotic division.
Interested? Why not read the article now! As with all our Cover articles, it will be FREE to access for the next 6 weeks.
2-Anilinonicotinyl linked 1,3,4-oxadiazole derivatives: Synthesis, antitumour activity and inhibition of tubulin polymerization Ahmed Kamal, Y. V. V. Srikanth, Thokhir B. Shaik, M. Naseer A. Khan, Md. Ashraf, M. Kashi Reddy, K. Anil Kumar and Shasi V. Kalivendi
Med. Chem. Commun., 2011, 2, 819-823 DOI: 10.1039/C0MD00177E
